Caring Deeply. Changing Lives

We measure success by our impact on patients we serve

Neurotrope BioScience (OTCQB:NTRP), formed in 2012, is at the forefront of the biotech industry and is focused on developing new therapies with Bryostatin 1 for the treatment of neurodegenerative diseases and developmental disorders.


Our experience, capabilities, and passion for innovative and novel drug therapies have enabled us to build a development pipeline that includes various treatment approaches with Bryostatin 1 for serious and difficult-to-treat diseases such as Alzheimer’s dementia and the Orphan diseases, Fragile X Syndrome (FXS) and Niemann-Pick Type C (NPC).


Looking toward the future, Neurotrope BioScience has teamed up with Stanford University to identify the next generation Bryostatin 1 from a group of synthetic compounds called Bryologs, designed after the naturally-occurring Bryostatin.



Alzeimer’s disease and Neurodegeneration Presentation


Click here to view


Corporate Presentation


Click here to view